IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients

Table 1 Demographic and cytokine information

	sALS	fALS	Control	Autoimmune disorder^a
n	28	4	10	4
Age (years)	57.8 (2.5)	67.0 (4.7)	56.6 (9.6)	58.7 (13.0)
M/F ratio	14/14	2/2	7/3	4/0
Duration (months)	24.5 (3.0)	16.0 (4.2)	N/A	N/A
FRS	32.3 (2.1)	31.5 (2.7)	N/A	N/A
IL-17A^b	64.2%*	75.0%	0.0%*	100.0%
IL-17A^c	5767.4 (2700.4)	937.3 (927.8)	7 (4.8)	9993.6 (1865.5)
IL-17A^d	1145.4 (317.9)⁺	984 (581.6)	6.7 (2.1)⁺	2815 (861.7)
IL-17A^e	1126.0 (320.1)⁺	1124.0 (594.9)	7.1 (2.4)⁺	2074.0 (709.8)

Data are expressed as mean (± standard error of mean)
a Patients with eczema or asthma
b IL-17% positive in the serum (sALS vs. healthy controls, p = 0.003)
c IL-17 (pg/mL) serum level (ALS patients vs. normal controls, p = 0.008)
d IL-17 (pg/mL) PBMC supernatant level (without stimulation)
e IL-17 (pg/mL) PBMC supernatant level (with stimulation by fibrillar WT SOD-1 (2 μg/mL))
* p < 0.003 sALS vs. control
⁺ p < 0.01 sALS vs. control

ISSN: 1742-2094